Literature DB >> 29398791

Plasma Cell Dyscrasias in India-2017 Updates.

Arihant Jain1, Pankaj Malhotra1.   

Abstract

Rapid advances are being made in the field of plasma cell dyscrasias. Many abstracts pertaining to the laboratory aspects, clinical features, treatment modalities and outcome of plasma cell dyscrasias were presented at Hematocon 2017. All the total of 24 abstracts pertaining to plasma cell dyscrasias presented at the Hematocon 2017 were reviewed. Out of them 10 were original research and 14 were case reports/short case series. The key findings of original research studies conducted in India are being summarized. Exciting research in the field of plasma cell dyscrasias is being carried out by various centers in the country. Data presented on various aspects of research in plasma cell disorders is encouraging. Multicentric research in the field plasma cell dyscrasias should be encouraged to highlight the various aspects of disease biology and challenges in management unique to our country.

Entities:  

Keywords:  India; Multiple myeloma; Plasma cell disorders

Year:  2017        PMID: 29398791      PMCID: PMC5786641          DOI: 10.1007/s12288-017-0910-0

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  14 in total

1.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

2.  Rituximab in CD20 positive multiple myeloma.

Authors:  P Moreau; L Voillat; L Benboukher; C Mathiot; C Dumontet; N Robillard; O Hérault; F Garnache; R Garand; N Varoqueaux; H Avet-Loiseau; J L Harousseau; R Bataille
Journal:  Leukemia       Date:  2007-02-01       Impact factor: 11.528

3.  Immunohistochemical analysis identifies two cyclin D1+ subsets of plasma cell myeloma, each associated with favorable survival.

Authors:  James R Cook; Eric D Hsi; Sarah Worley; Raymond R Tubbs; Mohamad Hussein
Journal:  Am J Clin Pathol       Date:  2006-04       Impact factor: 2.493

4.  Cyclin D1 overexpression in multiple myeloma. A morphologic, immunohistochemical, and in situ hybridization study of 71 paraffin-embedded bone marrow biopsy specimens.

Authors:  E Athanasiou; V Kaloutsi; V Kotoula; P Hytiroglou; I Kostopoulos; C Zervas; P Kalogiannidis; A Fassas; J I Christakis; C S Papadimitriou
Journal:  Am J Clin Pathol       Date:  2001-10       Impact factor: 2.493

5.  Cyclin D1 expression in multiple myeloma by immunohistochemistry: Case series of 14 patients and literature review.

Authors:  Somanath Padhi; Renu G'boy Varghese; Anita Ramdas
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

6.  Immunohistochemical evaluation of CD20 expression in patients with multiple myeloma.

Authors:  Irfan Yavasoglu; Gokhan Sargin; Gurhan Kadikoylu; Firuzan Kacar Doger; Zahit Bolaman
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-26

7.  Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.

Authors:  A J Greenberg; S Philip; A Paner; S Velinova; A Badros; R Catchatourian; R Ketterling; R A Kyle; S Kumar; C M Vachon; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-01-02       Impact factor: 11.037

8.  Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.

Authors:  Pratibha S Kadam Amare; Hemani Jain; Shraddha Nikalje; Manju Sengar; Hari Menon; Nitin Inamdar; P G Subramanian; Sumeet Gujral; Tanuja Shet; Sridhar Epari; Reena Nair
Journal:  Indian J Med Res       Date:  2016-10       Impact factor: 2.375

9.  Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study.

Authors:  Jia-jia Zhang; Wan-jun Sun; Zhong-xia Huang; Shi-lun Chen; Yu-ping Zhong; Ying Hu; Na An; Men Shen; Xin Li
Journal:  World J Surg Oncol       Date:  2014-07-28       Impact factor: 2.754

10.  Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Authors:  N Weinhold; C J Heuck; A Rosenthal; S Thanendrarajan; C K Stein; F Van Rhee; M Zangari; A Hoering; E Tian; F E Davies; B Barlogie; G J Morgan
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528

View more
  1 in total

1.  Myeloma at Cross Roads in India.

Authors:  Uday Yanamandra; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-08       Impact factor: 0.900

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.